Navigation Links
Smoking during pregnancy may impair thyroid function of mom and fetus
Date:1/13/2009

Chevy Chase, MDCigarette smoking during pregnancy is associated with potentially harmful changes in both maternal and fetal thyroid function, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

"We studied the influence of cigarette smoking on thyroid function of two groups of women at different stages of pregnancy one in the first trimester and the other in the third trimester," said Dr. Bijay Vaidya, Ph.D., of Peninsula Medical School at Royal Devon and Exeter Hospital in the United Kingdom, and coauthor of the study. "In both groups we found that smoking during pregnancy is associated with changes in the mothers' thyroid hormone levels."

Optimal maternal thyroid function during pregnancy is vital for a successful pregnancy outcome, said Dr. Vaidya. The adverse outcomes associated with thyroid dysfunction during pregnancy include increased risk of miscarriage, premature birth, low birth weight and impaired neuropsychological development of the baby.

Dr. Vaidya and his colleagues also measured thyroid hormone levels in the umbilical cord of babies born to smoking mothers and found that smoking-related changes in thyroid function extend to the fetus. Dr. Vaidya believes that impaired thyroid function in the fetus could have potentially harmful biological consequences.

The study also found that in mothers who stopped smoking during pregnancy their thyroid hormone levels were comparable to levels found in non-smokers, which suggests that changes in thyroid function are rapidly reversible.

There is currently no definitive explanation for how smoking affects thyroid function, but Dr. Vaidya suggests that smoking may influence thyroid hormone levels by affecting the enzyme which converts the active form of thyroid hormone to an inactive form.


'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Page: 1

Related biology news :

1. Smoking turns on genes -- permanently
2. Girls who begin dieting twice as likely to start smoking
3. Climate -- no smoking gun for Neanderthals
4. Cigarette smoking may accelerate disability in those with MS
5. New research explains link between smoking and SIDS
6. First trimester smoking linked to oral clefts
7. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
8. Low vitamin D during pregnancy linked to pre-eclampsia
9. Amazon forest shows unexpected resiliency during drought
10. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
11. Moms obesity during conception phase may set the stage for offsprings obesity risk

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2009)...ember 18, 2009 -- A butterfly,s proboscis looks li...-- but it works more like a paper towel, according...pes to borrow the tricks of this piece of insect a...uid inside of cells. , Kornev will present his w...erican Physical Society,s (APS) Division of Fluid ...
(Date:11/21/2009)...vember 20,2009 / b3c newswire / - KINAXO Biotech...cing round, gaining two new investors in the compa...NAXO reports that Jrgen Schumacher has been electe..., KINAXO shareholders Axel Ullrich, Hellmut Kirc...tutional investors Mountain Partners, BioM, High-T...
(Date:11/20/2009)...ve all read studies about the health benefits of h...e molecular level, where amino acids known as cyst...le than when paired up with other cysteines. , N...ng with colleagues in Belgium, have discovered a n...es. The research appears in the Nov. 20 issue of t...
Breaking Biology News(10 mins):KINAXO Completes Financing Round to Enhance Biomarker Development 2KINAXO Completes Financing Round to Enhance Biomarker Development 3Saving the single cysteine: New antioxidant system found 2Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 1Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 2Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 3Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 4Biovista Inc Announces Positive Efficacy Results in a Pre Clinical Trial of its BVA 601 Repositioned Drug for Epilepsy 12744 1Biovista Inc Announces Positive Efficacy Results in a Pre Clinical Trial of its BVA 601 Repositioned Drug for Epilepsy 12744 2B Braun Medical Inc Recognized by Industry for Manufacturing Influential Medical Devices 12742 1B Braun Medical Inc Recognized by Industry for Manufacturing Influential Medical Devices 12742 2B Braun Medical Inc Recognized by Industry for Manufacturing Influential Medical Devices 12742 3B Braun Medical Inc Recognized by Industry for Manufacturing Influential Medical Devices 12742 4
...xperts from Queen,s University Belfast have develo...quired infections that are resistant to antibiotic...t only kill colonies of these dangerous microbes, ... of these new antimicrobial agents was carried out...niversity Ionic Liquid Laboratories (QUILL) Resear...
...onserving Australia,s most endangered snake might ...posed. , The last remaining populations of broad-...woodland that is destroying their habitat, a study...tanford University (USA) has shown. , "Broad-head...ithin 200 km of Sydney, and those small communitie...
...IAMI University of Miami,s (UM,s) Rosenstiel Scho... announce they have received two grants totaling $...und. One award for $51,000 will be used to re-ener...ogram aboard Royal Caribbean International,s Explo...ted with ocean and atmospheric science laboratorie...
Other Biology News:Queen's scientists find new way to battle MRSA 2Australia's most endangered snake might need burning 2The University of Miami receives grants from Royal Caribbean Cruises Ltd.'s Ocean Fund 2
(Date:11/19/2009)... BLAUVELT, N.Y., Nov. 19 Dr. Mate ...xtract, responds to a press release issued on Nove...ian company for making false and self-serving stat...ces. ,, Dr. Hidvegi stated from his office in ...at research on Avemar does not apply to AveULTRA, ...
(Date:11/19/2009)... NEW YORK, Nov. 19 NeoSt...it has sent the following letter to its shareholde...er 30, 2009, of China Biopharmaceuticals Holdings,...pany based in the People,s Republic of China. The ... Suzhou Eyre Pharmaceutical Co. Ltd., CHBP,s prima...
(Date:11/19/2009)..., MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRN...Decision Resources find that the leading driver of...urope is broad-spectrum activity against gram-posi...ty of organisms that can cause nosocomial pneumoni...ook primarily for agents that provide appropriate ...
(Date:11/19/2009)... MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeut...atient in a randomized Phase 2B study of AEG35156,...elopment for multiple oncology indications. ,, ...e 2 Study of the X-Linked Inhibitor of Apoptosis (... High-dose Cytarabine and Idarubicin in AML Follow...
Breaking Biology Technology:American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...Hospitalist Company, Inc. (Nasdaq: IPCM ), a lead... today reaffirmed its guidance for full year 2008,... million and full year,2008 earnings per adjusted ...ncurred in the first quarter related to the Compan...ent the impact of acquisitions, the Company,typica...
...nounced today,that it received FDA 510(k) clearanc...em for Positron Emission Tomography/Computed Tomog...TM) PET Infusion System is the,first infusion syst...FDG,delivery process., (Logo: http://www.newscom...mating and controlling the FDG delivery process, t...
...reholders Believe It Reflects,Unwillingness To Con...ck of Industry Knowledge...on BetterBiovail.com All Shareholders Urged to Se... June 17 The Concerned Shareholders,of Biovail Co...a refusal by,Biovail CEO William Wells to particip...
Other Biology Technology:IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 2IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 3IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008 4MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 3Biovail Concerned Shareholders Want Open Debate 2Biovail Concerned Shareholders Want Open Debate 3
Rabbit Anti-Human NIRF Polyclonal Antibody, Unconjugated from Abcam
Acc I from Invitrogen
SexA I from New England Biolabs
Psp1406 I from Takara Mirus Bio
Biology Products: